Welcome to our dedicated page for Nkarta SEC filings (Ticker: NKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nkarta, Inc. filings document the regulatory record of a clinical-stage biotechnology company advancing engineered NK cell therapies for autoimmune disease. Recent 8-K reports disclose quarterly and annual financial results, corporate highlights, and clinical-program references for NKX019 and the Ntrust studies.
The company’s proxy materials cover annual meeting governance, director elections, auditor ratification, executive compensation votes, and stockholder voting mechanics. Other filings describe capital-raising infrastructure, including a Form S-3 registration statement and an at-the-market sales agreement for common stock, as well as emerging growth company reporting status and related Exchange Act disclosures.
Nkarta, Inc. held its 2026 annual meeting of stockholders on June 10, 2026. Stockholders elected Class III directors Ali Behbahani and Zachary Scheiner to terms running until the 2029 annual meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Stockholders approved, on a non-binding advisory basis, the compensation paid to the company’s named executive officers and voted on how often to hold future say-on-pay votes. Based on the vote, the company will hold advisory executive compensation votes every year until the next required frequency vote.
Nkarta, Inc. reported a Form 4 showing a compensation-related stock option grant connected to RA Capital–affiliated entities. An option over 37,000 shares of common stock was awarded with a $2.46 exercise price, vesting 100% on June 10, 2027 or before the first annual stockholder meeting after grant, with accelerated vesting upon a change in control, death, or disability. The option is held by Dr. Scheiner for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund LP, and the reporting persons disclaim beneficial ownership except for any pecuniary interest.
Nkarta, Inc. director Ali Behbahani reported receiving a stock option grant covering 37,000 shares of common stock. The option has an exercise price of $2.46 per share and expires on June 9, 2036.
All 37,000 shares subject to the option vest 100% on the first to occur of June 10, 2027 or the day immediately before the first annual stockholder meeting after the grant date. The award becomes fully vested earlier if there is a defined change in control of Nkarta or if Behbahani’s service ends due to death or disability. Following this grant, he directly holds options for 37,000 underlying shares.
Nkarta, Inc. director George Simeon received a stock option grant for 37,000 shares of Common Stock. The option has an exercise price of $2.4600 per share and expires on June 9, 2036. All shares subject to the option vest 100% on the earlier of June 10, 2027 or the day immediately before the first annual meeting of stockholders after the grant date. The award becomes fully vested if there is a described "change in control" or if Simeon’s service ends because of death or "disability" as defined in the award agreement.
Nkarta, Inc. director George Vratsanos received a grant of stock options covering 37,000 shares of common stock at an exercise price of $2.46 per share. This is a compensation-related award, not an open-market purchase.
All 37,000 option shares vest 100% on the earlier of June 10, 2027 or the day immediately before the first annual stockholder meeting following the grant date. The options become fully vested earlier if there is a qualifying change in control of Nkarta or if Vratsanos separates from service due to death or disability before that time.
Nkarta, Inc. director Zachary Scheiner reported an award of stock options covering 37,000 shares of common stock at an exercise price of $2.46 per share. The options vest 100% on the earlier of June 10, 2027 or the day before the first annual stockholder meeting after the grant, and expire on June 9, 2036. Under an arrangement with RA Capital Management, L.P., Scheiner holds the option for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P. and disclaims beneficial ownership of the option and underlying shares.
Nkarta, Inc. director Patterson Leone D received a grant of stock options covering 37,000 shares of common stock at an exercise price of $2.46 per share. The options vest 100% on the earlier of June 10, 2027 or the day before the first annual stockholder meeting after the grant date.
These options expire on June 9, 2036 and will fully vest if there is a qualifying change in control, or if the director’s service ends due to death or disability. This filing reflects a compensation-related award rather than open-market buying or selling.
Nkarta, Inc. director Michael Dybbs received a stock option grant covering 37,000 shares of common stock. The option has an exercise price of $2.46 per share and expires on June 9, 2036.
All 37,000 shares vest 100% on the earlier of June 10, 2027 or the day before the first annual stockholder meeting after the grant date, and become fully vested sooner if there is a change in control of Nkarta, or if Dybbs separates from service due to death or disability.
Nkarta, Inc. director Angela Thedinga received a grant of stock options covering 37,000 shares of common stock at an exercise price of $2.46 per share. The options vest 100% on the earlier of June 10, 2027 or the day before the first annual stockholder meeting after the grant date, with full vesting upon certain change in control, death, or disability events.
New Enterprise Associates 15, L.P. and affiliates filed Amendment No. 3 to their Schedule 13D on Nkarta, Inc. They report beneficial ownership of 3,568,781 shares of Nkarta common stock, representing 4.9% of the shares outstanding based on 71,545,358 shares reported as of May 7, 2026. The filing states they have ceased to beneficially own five percent or more of Nkarta’s common stock as of May 12, 2026, primarily due to an increase in the company’s outstanding shares. The NEA entities describe their holdings as for investment purposes and indicate no current plans for corporate actions such as mergers, asset sales, or board changes.